Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

Inclusion Criteria:

1. Age ≥18 years

2. Newly diagnosed patients with Ph+ CML in CP, with or without the presence of othercytogenetic abnormalities at the time of diagnosis

3. Treatment naïve patients with confirmed diagnosis within 3 months of study enrolment

4. Levels of liver aminotransferases and serum bilirubin ≤ 2 times the upper limit ofthe normal range, and serum creatinine ≤1.5 times the upper limit of the normalrange

5. Written informed consent

Exclusion Criteria:

1. CML in accelerated phase (AP) at enrolment except patients in AP with the presenceof other cytogenetic abnormalities at the time of diagnosis 2. CML in BP atenrolment 3. Patients who meet any of the contraindications to the administration ofthe study drug according to the approved Summary of Product Characteristics.